Mass spec data digital transformation at Lilly Biologics Discovery
Mass spectrometry (MS) now produces richer, more complex datasets than ever, offering biopharmaceutical teams new opportunities to deepen biological insight and accelerate discovery. Unlocking this potential requires transforming raw MS outputs into structured, automated, and analysis‑ready data that can support scalable workflows, reproducible analytics, and AI‑driven prediction models.
In this SelectScience® webinar, learn from Dr. Joomi Ahn, Senior Director at Eli Lilly, as she shares how the Biologic Discovery Mass Spectrometry group implemented Genedata Expressionist to build an integrated digital ecosystem. By connecting electronic lab notebooks, liquid‑handling automation, and custom artificial intelligence and machine‑learning tools, the team achieved 3–10× productivity gains.
By registering for this webinar, you will hear first‑hand how these capabilities now enable high‑throughput intact mass analysis, bispecific assembly checks, and stability peptide mapping. This flexible, vendor‑neutral foundation can help teams accelerate their workflows and unlock insights that drive the next wave of biologic drug discovery.
What will this webinar cover?
- How to standardize MS workflows across sites with a scalable, vendor-neutral, flexible platform
- How to automate end-to-end MS processes to increase productivity, data integrity, and knowledge access
- How to integrate wet and digital labs to shorten developability timelines for any new and hybrid modality
- How to leverage sequence liability prediction and automated stability reporting to accelerate drug candidate selection
Who should attend?
- Analytical scientists and innovation leaders looking for scalable, vendor-neutral ways to standardize and automate MS workflows across labs and sites.
- Developability and CMC characterization stakeholders using MS data and digital platforms to streamline biologics discovery and development, reduce optimization cycles, and accelerate timelines.
- VP/Director-level biopharma leaders building digital foundations in R&D and evaluating how AI and digital tools can accelerate timelines and deliver measurable impact.
- IT, informatics, and scientific software developers integrating legacy systems, enabling scalable infrastructure, and delivering user-friendly tools that strengthen scientific workflows.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing [email protected].
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speaker: Dr. Joomi Ahn (Senior Director, Mass Spec Analytical BioTDR, Eli Lilly)
Dr. Joomi Ahn is a Senior Director at Eli Lilly and Company, where she leads the Mass Spectrometry Analytical Group within Biologics Discovery at the San Diego site. With more than 25 years of biopharmaceutical industry experience at AstraZeneca, AbbVie, and Waters Corporation, she has contributed to multiple protein therapeutic pipelines across early- to late-stage analytical and process development. Dr. Ahn holds a Ph.D. in Chemistry and Chemical Biology from Northeastern University, has authored 13 peer-reviewed publications, and is a co-inventor on a granted patent.
Moderator: Ada Yee (Scientific Communications & Engagement, Corporate, Genedata)
Ada Yee is a scientific communications professional dedicated to helping scientists and leaders communicate complex ideas clearly and effectively. With an academic background at Berkeley and Stanford, she brings a strong foundation in research communication and a passion for impactful scientific storytelling.
Moderator: Olivia Long (Editorial Team, SelectScience)
Olivia Long is a science editor specializing in pharmaceutical and applied science. She has a BSc in Pharmacology, and an MSc in Neuroscience, where she investigated neuro‑oncology drug‑resistance pathways using patient‑derived cell models. Her laboratory experience spans R&D hygiene testing, controlled‑environment sample production, and protocol development, giving her a broad understanding of analytical workflows and the scientific principles underpinning biopharmaceutical quality control.
